# A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

> **NCT00466440** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 108 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** placebo
- **DRUG:** docetaxel
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00466440
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-08
- **Final completion:** 2010-06
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00466440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00466440, "A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00466440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*